Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Minato-Ku, Tokyo, Japan.
Division of Gastroenterology, Department of Internal Medicine, Fuji City General Hospital, Fuji-Shi, Shizuoka, Japan.
BMC Gastroenterol. 2023 Jun 5;23(1):196. doi: 10.1186/s12876-023-02835-y.
Osteosarcopenia, defined as the coexistence of sarcopenia and osteoporosis, is associated with adverse clinical outcomes. The present study investigated the prognostic significance of osteosarcopenia in patients with cirrhosis.
This retrospective study evaluated 126 patients with cirrhosis. Participants were classified into three groups based on the presence or absence of (1) sarcopenia and/or osteoporosis; and (2) Child-Pugh (CP) class B/C cirrhosis and/or osteosarcopenia, and the cumulative survival rates were compared between the groups. Cox proportional hazards model was used to identify independent factors associated with mortality. Sarcopenia and osteoporosis were diagnosed according to the Japan Society of Hepatology and the World Health Organization criteria, respectively.
Among the 126 patients, 24 (19.0%) had osteosarcopenia. Multivariate analysis identified osteosarcopenia as a significant and independent prognostic factor. The cumulative survival rates were significantly lower in patients with osteosarcopenia than in those without (1/3/5-year survival rates = 95.8%/73.7%/68.0% vs. 100%/93.6%/86.5%, respectively; p = 0.020). Patients with osteosarcopenia, but not sarcopenia or osteoporosis alone, had significantly lower cumulative survival rates than those without both conditions (p = 0.019). Furthermore, patients with both CP class B/C and osteosarcopenia had significantly lower cumulative survival rates than those without both (p < 0.001) and with either condition (p < 0.001).
Osteosarcopenia was significantly associated with mortality in patients with cirrhosis. The cumulative survival rates were lower in patients with osteosarcopenia than in those without both conditions. Additionally, comorbid osteosarcopenia worsened the prognosis of patients with CP class B/C. Therefore, simultaneous evaluation of both sarcopenia and osteoporosis is crucial to better predict the prognosis.
骨肌减少症定义为肌少症和骨质疏松症的共存,与不良临床结局相关。本研究旨在探讨骨肌减少症在肝硬化患者中的预后意义。
本回顾性研究纳入了 126 例肝硬化患者。根据是否存在(1)肌少症和/或骨质疏松症;(2)Child-Pugh(CP)B/C 级肝硬化和/或骨肌减少症,将患者分为三组,并比较各组的累积生存率。采用 Cox 比例风险模型确定与死亡率相关的独立因素。肌少症和骨质疏松症分别根据日本肝病学会和世界卫生组织标准诊断。
在 126 例患者中,24 例(19.0%)患有骨肌减少症。多因素分析显示,骨肌减少症是独立的预后不良因素。骨肌减少症患者的累积生存率显著低于无骨肌减少症患者(1/3/5 年生存率分别为 95.8%/73.7%/68.0%和 100%/93.6%/86.5%;p=0.020)。与不伴肌少症和骨质疏松症的患者相比,仅伴骨肌减少症的患者累积生存率显著更低(p=0.019)。此外,同时伴 CP 级 B/C 和骨肌减少症的患者累积生存率显著低于既不伴这两种疾病又不伴任何一种疾病的患者(p<0.001),以及仅伴任何一种疾病的患者(p<0.001)。
骨肌减少症与肝硬化患者的死亡率显著相关。伴骨肌减少症的患者的累积生存率低于既不伴这两种疾病又不伴任何一种疾病的患者。此外,CP 级 B/C 合并骨肌减少症会使患者的预后恶化。因此,同时评估肌少症和骨质疏松症对更好地预测预后至关重要。